{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:17Z","timestamp":1791666137672,"version":"4.3.4"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_med-2026-1440_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>With the recognition of membranous nephropathy as an autoimmune disease, targeting B-cells has emerged as an effective therapeutic agent for primary membranous nephropathy (PMN). About up to 40\u202f% of patients fail to respond to rituximab (RTX). Obinutuzumab is a humanized and glycoengineered type II anti-CD20 monoclonal antibody which demonstrates more powerful and prolonged B-cell depletion to rituximab in certain hematologic malignancies. Our aim was to observe the efficacy and safety of Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy and to find the factors associated with a poor response to Obinutuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1440_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of consecutive patients with biopsy-proven primary membranous nephropathy who received Obinutuzumab as rescue therapy for rituximab-resistant or rituximab-recurrent disease between September 2022 and March 2025. Obinutuzumab was administered as two separate 1\u202fg intravenous infusions over two to four weeks, with a subsequent 1\u202fg infusion at approximately six months in most patients. The treatment regimen was determined by the medical team based on the patient\u2019s clinical condition and laboratory findings. We assessed the following outcomes: clinical remission rate, immunological remission rate, relapse rate, and incidence of adverse events. Additionally, we explored potential factors associated with treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1440_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age at initiation of Obinutuzumab treatment was 46.5\u00a0\u00b1\u00a012.0 years. Patients with CKD stages 1\u20134 were48\u202f%, 24\u202f%, 20\u202f% and 8\u202f% respectively. Renal pathological findings revealed 15 cases of stage I membranous nephropathy, 6 cases of stage II membranous nephropathy, and 4 cases of atypical membranous nephropathy. Of the 25 patients, 20 were identified as rituximab-resistant, while 5 had recurrent disease after an initial response. During a median follow-up of nine months (range 6\u201330), complete or partial remission of proteinuria was achieved in 20 of the 25 participants (80\u202f%). The time to achieve clinical remission was four months (range 1\u201314). Among the 21 patients with anti-phospholipase A2 receptor antibody-associated primary membranous nephropathy, 13 simultaneously achieved immunologic remission. Relapse occurred in two patients following a nine-month period off medication. No clinically severe adverse events were observed during the treatment period. Higher baseline proteinuria (p=0.001) and serum creatinine levels (p=0.03) were associated with a poorer response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_med-2026-1440_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Obinutuzumab may represent a promising treatment strategy for rituximab-resistant and recurrent membranous nephropathy, including in cases with severe renal impairment. A poorer response to obinutuzumab may be associated with higher baseline proteinuria and serum creatinine levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2026-1440","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:10:39Z","timestamp":1781453439000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of obinutuzumab as rescue therapy for rituximab-resistant and rituximab-recurrent primary membranous nephropathy: a retrospective cohort study"],"prefix":"10.1515","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7878-4442","authenticated-orcid":false,"given":"Li","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1458-1710","authenticated-orcid":false,"given":"Huaying","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4895-1821","authenticated-orcid":false,"given":"Tianhua","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Orthopacdic Surgery , The Third Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6260-9335","authenticated-orcid":false,"given":"Mengsi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Breast and Thyroid Surgery Department , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8771-4386","authenticated-orcid":false,"given":"Shaomei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1851-9909","authenticated-orcid":false,"given":"Xi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3519-789X","authenticated-orcid":false,"given":"Xuzhi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1037-0071","authenticated-orcid":false,"given":"Lingling","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Nephrology , The Second Hospital of Hebei Medical University , Shijiazhuang , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061316555367923_j_med-2026-1440_ref_001","doi-asserted-by":"crossref","unstructured":"Keri, KC, Blumenthal, S, Kulkarni, V, Beck, L, Chongkrairatanakul, T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J 2019;95:23\u201331. https:\/\/doi.org\/10.1136\/postgradmedj-2018-135729.","DOI":"10.1136\/postgradmedj-2018-135729"},{"key":"2026061316555367923_j_med-2026-1440_ref_002","doi-asserted-by":"crossref","unstructured":"Troyanov, S, Wall, CA, Miller, JA, Scholey, JW, Cattran, DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004;66:1199\u2013205. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00873.x.","DOI":"10.1111\/j.1523-1755.2004.00873.x"},{"key":"2026061316555367923_j_med-2026-1440_ref_003","doi-asserted-by":"crossref","unstructured":"Fervenza, FC, Appel, GB, Barbour, SJ, Rovin, BH, Lafayette, RA, Aslam, N, et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N\u00a0Engl J Med 2019;381:36\u201346. https:\/\/doi.org\/10.1056\/nejmoa1814427.","DOI":"10.1056\/NEJMoa1814427"},{"key":"2026061316555367923_j_med-2026-1440_ref_004","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ju\u00e1rez, G, Rojas-Rivera, J, Logt, AV, Justino, J, Sevillano, A, Caravaca-Font\u00e1n, F, et al.. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 2021;99:986\u201398. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014.","DOI":"10.1016\/j.kint.2020.10.014"},{"key":"2026061316555367923_j_med-2026-1440_ref_005","doi-asserted-by":"crossref","unstructured":"Rojas-Rivera, J, Fervenza, FC, Ortiz, A. Recent clinical trials insights into the treatment of primary membranous nephropathy. Drugs 2022;82:109\u201332. https:\/\/doi.org\/10.1007\/s40265-021-01656-1.","DOI":"10.1007\/s40265-021-01656-1"},{"key":"2026061316555367923_j_med-2026-1440_ref_006","doi-asserted-by":"crossref","unstructured":"Dahan, K, Debiec, H, Plaisier, E, Cachanado, M, Rousseau, A, Wakselman, L, et al.. Rituximab for severe membranous nephropathy: a 6-Month trial with extended Follow-Up. J\u00a0Am Soc Nephrol 2017;28:348\u201358. https:\/\/doi.org\/10.1681\/asn.2016040449.","DOI":"10.1681\/ASN.2016040449"},{"key":"2026061316555367923_j_med-2026-1440_ref_007","doi-asserted-by":"crossref","unstructured":"Rovin, BH, Adler, SG, Barratt, J, Bridoux, F, Burdge, KA, Chan, TM, et al.. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 2021;100:753\u201379. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015.","DOI":"10.1016\/j.kint.2021.05.015"},{"key":"2026061316555367923_j_med-2026-1440_ref_008","doi-asserted-by":"crossref","unstructured":"Ruggenenti, P, Cravedi, P, Chianca, A, Perna, A, Ruggiero, B, Gaspari, F, et al.. Rituximab in idiopathic membranous nephropathy. J\u00a0Am Soc Nephrol 2012;23:1416\u201325. https:\/\/doi.org\/10.1681\/asn.2012020181.","DOI":"10.1681\/ASN.2012020181"},{"key":"2026061316555367923_j_med-2026-1440_ref_009","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner, E, Br\u00fcnker, P, Moser, S, P\u00fcntener, U, Schmidt, C, Herter, S, et al.. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979.","DOI":"10.1182\/blood-2009-06-225979"},{"key":"2026061316555367923_j_med-2026-1440_ref_010","doi-asserted-by":"crossref","unstructured":"Gagez, AL, Cartron, G. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 2014;26:484\u201391. https:\/\/doi.org\/10.1097\/cco.0000000000000107.","DOI":"10.1097\/CCO.0000000000000107"},{"key":"2026061316555367923_j_med-2026-1440_ref_011","doi-asserted-by":"crossref","unstructured":"Marcus, R, Davies, A, Ando, K, Klapper, W, Opat, S, Owen, C, et al.. Obinutuzumab for the first-line treatment of follicular lymphoma. N\u00a0Engl J Med 2017;377:1331\u201344. https:\/\/doi.org\/10.1056\/nejmoa1614598.","DOI":"10.1056\/NEJMoa1614598"},{"key":"2026061316555367923_j_med-2026-1440_ref_012","doi-asserted-by":"crossref","unstructured":"Reddy, V, Klein, C, Isenberg, DA, Glennie, MJ, Cambridge, G, Cragg, MS, et al.. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 2017;56:1227\u201337. https:\/\/doi.org\/10.1093\/rheumatology\/kex067.","DOI":"10.1093\/rheumatology\/kex067"},{"key":"2026061316555367923_j_med-2026-1440_ref_013","doi-asserted-by":"crossref","unstructured":"Su, X, Wu, B, Tie, X, Guo, X, Feng, R, Qiao, X, et al.. Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy. Kidney Int Rep 2024;9:2386\u201398. https:\/\/doi.org\/10.1016\/j.ekir.2024.05.004.","DOI":"10.1016\/j.ekir.2024.05.004"},{"key":"2026061316555367923_j_med-2026-1440_ref_014","doi-asserted-by":"crossref","unstructured":"Hudson, R, Rawlings, C, Mon, SY, Jefferis, J, John, GT. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases. BMC Nephrol 2022;23:134. https:\/\/doi.org\/10.1186\/s12882-022-02761-3.","DOI":"10.1186\/s12882-022-02761-3"},{"key":"2026061316555367923_j_med-2026-1440_ref_015","doi-asserted-by":"crossref","unstructured":"Klomjit, N, Fervenza, FC, Zand, L. Successful treatment of patients with refractory PLA(2)R-Associated membranous nephropathy with obinutuzumab: a report of 3 cases. Am J Kidney Dis 2020;76:883\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444.","DOI":"10.1053\/j.ajkd.2020.02.444"},{"key":"2026061316555367923_j_med-2026-1440_ref_016","doi-asserted-by":"crossref","unstructured":"Sridharan, K, Gopal, B, Wilson, S, Pham, A, Hutton, H. Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series. J\u00a0Nephrol 2025;38:1809\u20131818. https:\/\/doi.org\/10.1007\/s40620-025-02224-6.","DOI":"10.1007\/s40620-025-02224-6"},{"key":"2026061316555367923_j_med-2026-1440_ref_017","doi-asserted-by":"crossref","unstructured":"Lin, Y, Han, Q, Chen, L, Wang, Y, Ren, P, Liu, G, et al.. Obinutuzumab in refractory membranous nephropathy: a case series. Kidney Med 2024;6:100853. https:\/\/doi.org\/10.1016\/j.xkme.2024.100853.","DOI":"10.1016\/j.xkme.2024.100853"},{"key":"2026061316555367923_j_med-2026-1440_ref_018","doi-asserted-by":"crossref","unstructured":"Conversano, E, Debiec, H, Colucci, M, Emma, F, Ronco, P, Vivarelli, M, et al.. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance. Pediatr Nephrol 2024;39:305\u20138. https:\/\/doi.org\/10.1007\/s00467-023-06085-8.","DOI":"10.1007\/s00467-023-06085-8"},{"key":"2026061316555367923_j_med-2026-1440_ref_019","doi-asserted-by":"crossref","unstructured":"Beck, LHJr., Bonegio, RG, Lambeau, G, Beck, DM, Powell, DW, Cummins, TD, et al.. M-type phospholipase A2 receptor as target antigen\u00a0in idiopathic membranous nephropathy. N\u00a0Engl J Med 2009;361:11\u201321. https:\/\/doi.org\/10.1056\/nejmoa0810457.","DOI":"10.1056\/NEJMoa0810457"},{"key":"2026061316555367923_j_med-2026-1440_ref_020","doi-asserted-by":"crossref","unstructured":"Ginth\u00f6r, NE, Artinger, K, Pollheimer, MJ, Stradner, MH, Eller, K. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin Kidney J 2022;15:564\u20136. https:\/\/doi.org\/10.1093\/ckj\/sfab250.","DOI":"10.1093\/ckj\/sfab250"},{"key":"2026061316555367923_j_med-2026-1440_ref_021","doi-asserted-by":"crossref","unstructured":"Sethi, S, Kumar, S, Lim, K, Jordan, SC. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 2020;5:1515\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2020.06.030.","DOI":"10.1016\/j.ekir.2020.06.030"},{"key":"2026061316555367923_j_med-2026-1440_ref_022","doi-asserted-by":"crossref","unstructured":"Zhang, Y, Sun, J, Gao, J, Sun, W, Xu, L, Zhai, C, et al.. Case report: one case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia. Front Pharmacol 2024;15:1347880. https:\/\/doi.org\/10.3389\/fphar.2024.1347880.","DOI":"10.3389\/fphar.2024.1347880"},{"key":"2026061316555367923_j_med-2026-1440_ref_023","doi-asserted-by":"crossref","unstructured":"Naik, S, Shukla, S, Av, N, Kumar, V, Sekar, A, Nada, R, et al.. Obinutuzumab in refractory phospholipase A2\u00a0receptor-associated membranous nephropathy with severe CKD. Kidney Int Rep 2023;8:942\u20133. https:\/\/doi.org\/10.1016\/j.ekir.2023.01.035.","DOI":"10.1016\/j.ekir.2023.01.035"},{"key":"2026061316555367923_j_med-2026-1440_ref_024","doi-asserted-by":"crossref","unstructured":"Beck, LHJr., Fervenza, FC, Beck, DM, Bonegio, RG, Malik, FA, Erickson, SB, et al.. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J\u00a0Am Soc Nephrol 2011;22:1543\u201350. https:\/\/doi.org\/10.1681\/asn.2010111125.","DOI":"10.1681\/ASN.2010111125"},{"key":"2026061316555367923_j_med-2026-1440_ref_025","doi-asserted-by":"crossref","unstructured":"Ruggenenti, P, Debiec, H, Ruggiero, B, Chianca, A, Pell\u00e9, T, Gaspari, F, et al.. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J\u00a0Am Soc Nephrol 2015;26:2545\u201358. https:\/\/doi.org\/10.1681\/asn.2014070640.","DOI":"10.1681\/ASN.2014070640"},{"key":"2026061316555367923_j_med-2026-1440_ref_026","doi-asserted-by":"crossref","unstructured":"De Vriese, AS, Glassock, RJ, Nath, KA, Sethi, S, Fervenza, FC. A proposal for a serology-based approach to membranous nephropathy. J\u00a0Am Soc Nephrol 2017;28:421\u201330. https:\/\/doi.org\/10.1681\/asn.2016070776.","DOI":"10.1681\/ASN.2016070776"},{"key":"2026061316555367923_j_med-2026-1440_ref_027","doi-asserted-by":"crossref","unstructured":"Singh, S, Kumar, NK, Dwiwedi, P, Charan, J, Kaur, R, Sidhu, P, et al.. Monoclonal antibodies: a review. Curr Clin Pharmacol 2018;13:85\u201399. https:\/\/doi.org\/10.2174\/1574884712666170809124728.","DOI":"10.2174\/1574884712666170809124728"},{"key":"2026061316555367923_j_med-2026-1440_ref_028","doi-asserted-by":"crossref","unstructured":"Reddy, V, Dahal, LN, Cragg, MS, Leandro, M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today 2016;21:1330\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2016.06.009.","DOI":"10.1016\/j.drudis.2016.06.009"},{"key":"2026061316555367923_j_med-2026-1440_ref_029","doi-asserted-by":"crossref","unstructured":"Batten, M, Groom, J, Cachero, TG, Qian, F, Schneider, P, Tschopp, J, et al.. BAFF mediates survival of peripheral immature B lymphocytes. J\u00a0Exp Med 2000;192:1453\u201366. https:\/\/doi.org\/10.1084\/jem.192.10.1453.","DOI":"10.1084\/jem.192.10.1453"},{"key":"2026061316555367923_j_med-2026-1440_ref_030","doi-asserted-by":"crossref","unstructured":"Awasthi, A, Ayello, J, Van de Ven, C, Elmacken, M, Sabulski, A, Barth, MJ, et al.. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol 2015;171:763\u201375. https:\/\/doi.org\/10.1111\/bjh.13764.","DOI":"10.1111\/bjh.13764"},{"key":"2026061316555367923_j_med-2026-1440_ref_031","doi-asserted-by":"crossref","unstructured":"Podest\u00e0, MA, Trillini, M, Portalupi, V, Gennarini, A, Tomatis, F, Villa, A, et al.. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series. Am J Kidney Dis 2024;83:340\u20139.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.010.","DOI":"10.1053\/j.ajkd.2023.08.010"},{"key":"2026061316555367923_j_med-2026-1440_ref_032","doi-asserted-by":"crossref","unstructured":"Makker, SP, Kanalas, JJ. Course of transplanted heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J\u00a0Immunol 1989;142:3406\u201310. https:\/\/doi.org\/10.4049\/jimmunol.142.10.3406.","DOI":"10.4049\/jimmunol.142.10.3406"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1440\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:11:00Z","timestamp":1781453460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2026-1440\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/med-2026-1440"],"URL":"https:\/\/doi.org\/10.1515\/med-2026-1440","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20261440"}}